On the public citation graph

https://doi.org/10.2139/ssrn.4675164

0 signed · 36 inferred · view as graph

Inferred edges come from two machine sources: sweeps of open repository metadata (mostly SSRN and Zenodo), and a bulk OpenAlex citation snapshot. Every row below is labelled with the one it came from. Neither is a complete citation index — absence here is not evidence of absence.

Is this your work? Sign in with ORCID and put your name on the claims that are yours.
Claim with ORCID
Reference health. See whether every reference in this work resolves to a known work and none has been retracted — and get a dated CiteStamped badge you can embed.
See reference health

What this work says

Outgoing claims: the papers this work cites, builds on, or argues with.

inferredcites →https://doi.org/10.1016/j.jfineco.2022.08.004openalex-extracted
Count (and count-like) data in finance
inferredcites →https://doi.org/10.1016/j.jhealeco.2016.01.012openalex-extracted
Innovation in the pharmaceutical industry: New estimates of R&D costs
inferredcites →https://doi.org/10.1016/j.jpubeco.2012.10.003openalex-extracted
Market size and innovation: Effects of Medicare Part D on pharmaceutical research and development
inferredcites →https://doi.org/10.1038/d41573-022-00167-2openalex-extracted
Innovation in the Chinese pharmaceutical industry
inferredcites →https://doi.org/10.1038/nrclinonc.2017.10openalex-extracted
The changing landscape of clinical trial and approval processes in China
inferredcites →https://doi.org/10.1038/nrd.2017.70openalex-extracted
How much do clinical trials cost?
inferredcites →https://doi.org/10.1038/nrd3298openalex-extracted
Location of pharmaceutical innovation: 2000–2009
inferredcites →https://doi.org/10.1038/sdata.2018.42openalex-extracted
A database linking Chinese patents to China’s census firms
inferredcites →https://doi.org/10.1086/422563openalex-extracted
Innovating Firms and Aggregate Innovation
inferredcites →https://doi.org/10.1086/589934openalex-extracted
Do Faster Food and Drug Administration Drug Reviews Adversely Affect Patient Safety? An Analysis of the 1992 Prescription Drug User Fee Act
inferredcites →https://doi.org/10.1093/qje/qjz014openalex-extracted
The Effect of Minimum Wages on Low-Wage Jobs*
inferredcites →https://doi.org/10.1093/restud/rdab030openalex-extracted
Quasi-Experimental Shift-Share Research Designs
inferredcites →https://doi.org/10.1111/1756-2171.12113openalex-extracted
Market size and pharmaceutical innovation
inferredcites →https://doi.org/10.1162/0033553041382166openalex-extracted
Static and Dynamic Effects of Health Policy: Evidence from the Vaccine Industry
inferredcites →https://doi.org/10.1162/0033553041502144openalex-extracted
Market Size in Innovation: Theory and Evidence from the Pharmaceutical Industry
inferredcites →https://doi.org/10.1162/0033553053970214openalex-extracted
Competition and Innovation: An Inverted-U Relationship*
inferredcites →https://doi.org/10.1162/rest.88.4.641openalex-extracted
The Log of Gravity
inferredcites →https://doi.org/10.1186/s12992-017-0244-6openalex-extracted
Obstacles and opportunities in Chinese pharmaceutical innovation
inferredcites →https://doi.org/10.1257/089533002320950984openalex-extracted
Pharmaceuticals and the Developing World
inferredcites →https://doi.org/10.1257/aer.103.6.2169openalex-extracted
Trade Liberalization and Embedded Institutional Reform: Evidence from Chinese Exporters
inferredcites →https://doi.org/10.1257/aer.20131176openalex-extracted
Do Firms Underinvest in Long-Term Research? Evidence from Cancer Clinical Trials
inferredcites →https://doi.org/10.1257/aer.20181047openalex-extracted
Bartik Instruments: What, When, Why, and How
inferredcites →https://doi.org/10.1257/aer.20210107openalex-extracted
The Impact of Regulation on Innovation
inferredcites →https://doi.org/10.1257/aeri.20210063openalex-extracted
Insurance Design and Pharmaceutical Innovation
inferredcites →https://doi.org/10.1257/jel.20161327openalex-extracted
Economics of the Pharmaceutical Industry
inferredcites →https://doi.org/10.2139/ssrn.1306944openalex-extracted
Competition and Innovation: An Inverted U Relationship
inferredcites →https://doi.org/10.2139/ssrn.3751872openalex-extracted
Demand Shocks, Procurement Policies, and the Nature of Medical Innovation: Evidence from Wartime Prosthetic Device Patents
inferredcites →https://doi.org/10.2139/ssrn.4293625openalex-extracted
Regulatory Incentives for Innovation: The FDA's Breakthrough Therapy Designation
inferredcites →https://doi.org/10.2139/ssrn.4568759openalex-extracted
Committing to Grow: Privatizations and Firm Dynamics in East Germany
inferredcites →https://doi.org/10.2202/1558-9544.1013openalex-extracted
Assessing the Impacts of the Prescription Drug User Fee Acts (PDUFA) on the FDA Approval Process
inferredcites →https://doi.org/10.2307/2298044openalex-extracted
Quality Ladders in the Theory of Growth
inferredcites →https://doi.org/10.3386/w26679openalex-extracted
Demand Shocks, Procurement Policies, and the Nature of Medical Innovation: Evidence from Wartime Prosthetic Device Patents
inferredcites →https://doi.org/10.3386/w27563openalex-extracted
Insurance Design and Pharmaceutical Innovation
inferredcites →https://doi.org/10.3386/w30712openalex-extracted
Regulatory Incentives for Innovation: The FDA's Breakthrough Therapy Designation
inferredcites →https://doi.org/10.3386/w35095openalex-extracted
Homemade Foreign Trading
inferredcites →https://doi.org/10.3982/ecta5997openalex-extracted
An Empirical Model of Growth Through Product Innovation
Editorial review for independent work. ICSAC — the Institute for Complexity Science and Advanced Computing — runs a structured editorial panel for researchers publishing outside journals, and publishes on CiteStamp rails. Submission is free and goes through ORCID: icsacinstitute.org/submit.